Suc-Leu-Leu-Val-Tyr-AMC (LLVY-AMC)

Catalog number: SBB-PS0010, 2 mg

A Fluorogenic substrate for measuring the chymotrypsin-like peptidase activity of the 20S proteasome, calpains and other chymotrypsin-like proteases (Ex=345 nm and Em=445 nm).[1][2][3][4]

In stock


Suc-LLVY-AMC a 7-amino-4-methylcoumarin (AMC) labeled fluorogenic substrate can be used to measure the chymotrypsin–like activity of the 20S and 26S proteasome as well as calpains and other chymotrypsin-like proteases. Working concentrations of this substrate is 20-50 µM. Cleavage of the peptide by the enzymes liberates the fluorophore AMC which generates strong increase in fluorescence fluorescent that can be monitored fluorimetrically at Ex=345 nm and Em=445 nm.

For Research Use Only, Not For Use In Humans.


Product Overview
Quantity: 2.0 mg
Molecular Weight: 763.9 Da
Purity: >99% by HPLC
Readout: Endpoint / Kinetic
Label or Dye: 7-Amino-4-methylcoumarin
Detection Method: Fluorescence
Substrate Properties: Protein-Based Substrate, C40H53N5O10 , CAS#94367-21-2
Excitation/Emission (nm): 345/445
Storage Buffer: Lyophilized
Storage Store at 4°C after product arrival. After preparing a stock in DMSO ( ≥10 mM) store product at -20°C to −80°C. It is recommended to make multiple aliquots after the first thaw to ensure best performance.

Figures & Data


Figure 1. Suc-LLVY-AMC, Chemical Structure.
Structure of Suc_LLVY-AMC, CAS # 94367-21-2

Immunoproteasome Activity

Figure 2. 20S Immunoproteasome vs. 20S Constitutive Proteasome Activity.
LLVY-AMC exhibits a high specific activity for both immuno and constitutive proteasome compared to other substrates. Specific activities are higher when using immunoproteasome.

Certificates of Analysis (COA)

Citations & References

1) Dammer, E. et al. (2011). Polyubiquitin Linkage Profiles in Three Models of Proteolytic Stress Suggest the Etiology of Alzheimer Disease. J Biol Chem doi: 10.1074/jbc.M110.149633.

2) Gallery, M. et al. (2007). The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol Cancer Ther 6, 262.

3) Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy: J. Li, et al.; J. Mol. Cell. Cardiol. 102, 53 (2016), Abstract;